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Purpose: In the presence of random uncertainties, delivered radiation treatment doses in patient likely exhibit a
statistical distribution. The expected dose and variance of this distribution are unknown and are most likely not
equal to the planned value since the current treatment planning systems cannot exactly model and simulate
treatment machine. Relevant clinical questions are 1) how to quantitatively estimate the expected delivered dose
and extrapolate the expected dose to the treatment dose over a treatment course and 2) how to evaluate the
treatment dose relative to the corresponding planned dose. This study is to present a systematic approach to
address these questions and to apply this approach to patient-specific IMRT (PSIMRT) plan verifications.
Methods: The expected delivered dose in patient and variance are quantitatively estimated using Student T
distribution and Chi Distribution, respectively, based on pre-treatment QA measurements. Relationships between
the expected dose and the delivered dose over a treatment course and between the expected dose and the
planned dose are quantified with mathematical formalisms. The requirement and evaluation of the pre-treatment
QA measurement results are also quantitatively related to the desired treatment accuracy and to the to-be-
delivered treatment course itself. The developed methodology was applied to PSIMRT plan verification procedures
for both QA result evaluation and treatment quality estimation.
Results: Statistically, the pre-treatment QA measurement process was dictated not only by the corresponding plan
but also by the delivered dose deviation, number of measurements, treatment fractionation, potential uncertainties
during patient treatment, and desired treatment accuracy tolerance. For the PSIMRT QA procedures, in theory, more
than one measurement had to be performed to evaluate whether the to-be-delivered treatment course would
meet the desired dose coverage and treatment tolerance.
Conclusion: By acknowledging and considering the statistical nature of multi-fractional delivery of radiation
treatment, we have established a quantitative methodology to evaluate the PSIMRT QA results. Both the statistical
parameters associated with the QA measurement procedure and treatment course need to be taken into account
to evaluate the QA outcome and to determine whether the plan is acceptable and whether additional measures
should be taken to reduce treatment uncertainties. The result from a single QA measurement without the
appropriate statistical analysis can be misleading. When the required number of measurements is comparable to
the planned number of fractions and the variance is unacceptably high, action must be taken to either modify the
plan or adjust the beam delivery system.
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Successful radiation treatment depends on precise cali-
bration of the treatment machine and on the machine’s
accuracy and precision in delivering that particular treat-
ment plan. Protocols have been established to standardize
the treatment machine calibration process in order to im-
prove the accuracy of radiation dosimetry [1-5]. Similarly,
various treatment quality assurance (QA) protocols and
recommendations have been established and followed in
many radiation treatment centers [6-10]. These protocols
and recommendations typically involve dosimetric mea-
surements, which must then be correctly interpreted in
order to ensure proper radiation delivery and patient
safety.
One of the major goals of radiation treatments is to
deliver the desired dose coverage to the target volume. The
dose coverage is determined based on dose computations
by a treatment planning system (TPS) and is hopefully
achieved by the radiation treatment machine. In the
presence of random uncertainties arising from various
components of the treatment machine, and given an
infinite number of deliveries, the delivered doses would
exhibit a statistical distribution with an expected variance
and expected mean value. The expected mean delivered
value is most likely not equal to the corresponding planned
dose because current treatment planning systems do not
perfectly model treatment machines. Furthermore, since a
treatment course consists of a finite number of fractions,
the mean value of the delivered doses over the treatment
course may well differ from the expected mean value from
an infinite number of fractions. Though the treatment goal
is often stated simply as a desired dose (planned dose)
delivered to a patient, it would be more accurate to state
the goal as delivering a mean dose over a treatment course
to a patient within a certain confidence interval (e.g., 95%
confidence interval of 3%) around the desired dose. It has
been generally accepted that delivered dose to patient
should be within 5% of desired one with a 95% confidence
level [11,12], and its precision is affected by uncertainties
in every step of radiation treatment process. The goal of
this paper is to focus on the radiation delivery step and
to present an approach to estimate and evaluate whether
to-be-delivered doses over a treatment course meet the
treatment goal during the radiation delivery.
For more complicated treatment deliveries such as IMRT,
patient-specific IMRT (PSIMRT) plan verification QA
is usually performed. The purpose of the PSIMRT is to
verify the computed dose distribution of a plan is accurate
by conducting measurements in (typically) homogeneous
phantoms. If the PSIMRT result is deemed acceptable
according to certain criteria, the implicit assumption is that
the plan, when delivered to patient via a same delivery sys-
tem, will deliver similarly acceptable doses. The ultimate
aim of PSIMRT QA is to ensure plan integrity at treatmentand agreement (within a certain tolerance) between deliv-
ered and planned dose over a course of treatment. In
PSIMRT QA, even after the integrity of plan transfer and
treatment machine performance is thoroughly inspected
and verified, the existence of measurement uncertainties
is well-documented [13,14], and investigations have been
conducted to incorporate those uncertainties into IMRT
treatment delivery and planning [15,16]. With these
uncertainties, it is almost certain that repeated PSIMRT
QA measurements will produce a statistical distribution.
Therefore, it may be inappropriate to draw a conclusion
from PSIMRT QA based on a single measurement. For
example, under conditions of correct plan transfer, normal
machine function, and proper measurement equipment, it
is a relatively common scenario where an initial PSIMRT
QA measurement fails to meet pre-set criteria [17,18],
then subsequently passes on repeat measurement, and a
decision must be made whether the plan is acceptable or
not. Obviously, according to the general statistical theories,
the final decision should not completely ignore the initial
failure even if subsequent measurements are acceptable.
The decision should be based on statistical analysis of the
QA measurements including both the failed and passing
results and the expected treatment goal. Furthermore,
it is intuitive that a treatment course of fewer fractions
requires a higher standard in the distribution of its QA
results, e.g., for stereotactic body radiotherapy (SBRT).
Therefore, the ultimate goal of PSIMRT QA should be
three-fold: (1) and most importantly to verify the integrity
of plan transfer from the TPS to the treatment unit, to
identify major discrepancy such as beam modeling errors,
and accelerator/MLC performance, (2) to check the deliv-
erability of the plan, and (3) to evaluate the variation of
the plan delivery would be within the statistical tolerance
of the treatment prescription based on the fractionation
scheme and the measured variation.
In general, there are two types of errors: systematic errors
and random errors. Systematic errors are normally caused
by inaccuracy in a system or a tendency to consistently be
off from a predicted value. Random errors are unpredict-
able, unknown, and fluctuating variations. Several studies
have demonstrated that a finite number of fractions lead to
residual errors in total doses delivered to patient [19-21].
According to statistical theory, for a dose quantity of
random errors, the expected value and expected standard
deviation (SD) of its statistical distribution are unknown
but can be estimated using results from a number of re-
peated and independent measurements. In many cases,
the measured mean and standard deviation are directly
used as the expected value and expected standard deviation,
respectively. However, substitution of a measured mean
value for an expected value is scientifically meaningful
only if a confidence interval and its corresponding con-
fidence level for the substitution are clearly specified.
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are highly dependent on the number and variance of
measurements. With the expected value and expected
SD of the dose quantity statistically determined, based on
the “finite-sample distribution theory” of a given statistics,
the mean value distribution of the dose quantity delivered
over a limited number of fractions can be statistically esti-
mated and is highly dependent on the number of fractions.
Therefore, theoretically, the evaluation of PSIMRT plan
verification QA results (and other similar dosimetric meas-
urement procedures) should not be based on a preselected
value or a single observation of pass/fail. Rather it should
be based on a statistical approach incorporating the
number and variance of measured results, the associated
accuracy confidence interval and level, and related treat-
ment details such as number of fractions, uncertainties
during treatment, and desired dosimetric tolerance. Add-
itionally, uncertainties exist in the measurement equipment
and measurement setups. These uncertainties should also
be carefully analyzed and taken into consideration for the
evaluation of measurement results.
The current study is attempted to build a closed and
complete statistical model and expand the scope of the
newly improved statistical model and method to in-
clude another realm where such a method would be
beneficial: dosimetry and PSIMRT plan verification
QA measurements
Materials and methods
In the subsequent sections, unless otherwise stated, the
term dose or dose value is referred to the dose at a specific
point in patient or phantom.
For clarification, a few notations are first defined:
 PDX: Percent Difference between the expected value
and mean value of subject X;
 P: Probability of the subject of interest;
 N: Number of fractions of a treatment course
 n: Number of pre-treatment QA measurements
 R: the expected dose value at a point in QA
measurement
 σ2: the expected dose variance at a point in QA
measurement
 Rn: the mean of measured results for dose at a point
from n pre-treatment QA measurements
 σ 2n: the variance of measured results for dose at a
point from n pre-treatment QA measurements
 RN : the mean dose quantity at a point delivered over
N fractions of treatment
 σ2N : the variance of the mean dose quantity at a
point delivered over N fractions of treatment
For complicated treatments and plans, such as those
involving IMRT and requiring higher delivery accuracy,the questions are 1) how to estimate to-be-delivered dose
over a treatment course and its deviation from the planned
dose, 2) how to use pre-treatment QA measurements to
infer these dose estimates for the to-be-delivered treatment
and evaluate the QA outcome accordingly.
Assuming all machine components and the plan transfer
are within specification, in a typical PSIMRT plan verifica-
tion QA procedure, the current practice is to conduct
measurement and compare the measured result to the
corresponding planned value, typically in a homogeneous
phantom. If the difference is smaller than certain preset
criteria, the IMRT treatment design is deemed acceptable.
As discussed above, the delivered radiation dose most likely
exhibits a statistical distribution if repeated, even using
the same IMRT plan and radiation treatment machine.
Furthermore, the average dose and its deviation over a
treatment course also present a statistical distribution
and vary with the number of treatment fractions. Thus,
a more scientific approach to PSIMRT plan verification
QA procedures is not to simply compare the QA results
with the corresponding plan value(s) but to adopt a
systematic approach to conduct statistical analysis on
the QA results, taking into account treatment details
such as the number of fractions and desired deviation
tolerance.
General formalism for measurement statistical analysis
Assuming a dose quantity has uncertainties (random) and
its value follows a certain statistical distribution if it is
delivered an infinite number of times, there exist an
expected value R and an expected variance σ2 for this dose
quantity. There are two types of statistical estimations for
this dose quantity: 1) estimation of the expected R and σ2
by conducting n measurements and 2) estimation of
the mean value and variance of the dose quantity when
it is to be delivered for a limited number N times.
While pre-treatment measurements of a dose quantity
fall into the first type, the second type is analogous to
the estimation of the dose delivered to a patient over a
treatment course. In this study, it is assumed that the
statistical distribution of a dose quantity follows a Normal
Distribution.
Estimation of the percent difference between the expected
and QA measured results
Statistically, the expected value R is not exactly
known for almost all cases. To determine the expected
value, n independent measurements are conducted
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freedom and has the probability density function (16)
f tð Þ ¼ Γ n=2ð Þﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ















n−1 are the mean
value and the variance of the n measurement results,
respectively, and Γ(x) is the Gamma function and can be
expressed as Γ xð Þ ¼ ∫∞0 yx−1e−ydy . It should be noted that
the expected variance σ2 is different from σ 2n . Whereas σ
2
n
is a measured quantity, the expected variance σ2 ¼ lim
n→∞
σ 2.
The probability of quantity T satisfying condition a ≤T ≤ b
is computed as
P a ≤T≤ bð Þ ¼ ∫ba f tð Þ dt ð3Þ


































In Eq. 4, R−
Rn
Rn
100% , denoted as PDR, is the percent
difference between the expected result for the procedure
under consideration and the mean value of the measure-
ment results. From the equation, it is apparent that the
probability distribution of PDR is independent of the
expected variance σ2 and can be determined with the pa-
rameters of a particular measurement process, such as the
number, the mean and variance of the measured results.
From Eqn. 4, the probability of |PDR| ≤ y%, y ≥ 0 (the
probability of the measurement accuracy being within y%)
can be determined as























Equation (5) indicates that the probability of measure-
ment accuracy is dependent on the number (n), mean
(Rn ) and deviation (σ n ) of the measurement results and
can be computed directly from the measurement process
itself.
It should be emphasized that the expected value is
unknown unless there exists zero uncertainty. What areknown from a measurement procedure are the measure-
ment results and their distribution.
Estimation of the expected standard deviation




σ follows “Chi Distribution”
with n-1 degrees of freedom, with a probability density
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and t ≥ 0.









E σ nð Þ is the expected value of σ n . σ can be estimated








Probability determination of the percent difference between
the expected measurement value and a given value
As stated previously, the dose from the treatment plan
(given value) is most likely not equal to the expected
dose delivered by the treatment machine.
Suppose a given value is Rgiven and the expected mea-















































where a and b are two values to be determined.
The probability for R−RgivenRgiven 100%
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Estimation of the dose delivered to a patient over a
treatment course
Assume that the dose uncertain variance in a fraction of
radiation treatment is σ2 ¼ σ2other þ σ2m , where σ2m is the
uncertain variance originated from radiation delivery
machine and σ2other is that from all other sources including
patient setup, organ motion, etc. For a treatment course
of N fractions, the mean dose RN over the course follows
a normal distribution with the expected value R and a
variance σ2N ¼ σ
2
N :









p e−N t−Rð Þ2σ2 dt ð9Þ
It can be inferred from Eqn. 9 that for a treatment
course with a large number of fractions the mean value
of a dose quantity delivered to the patient is likely to be
close to the expected value even if the dose delivery
uncertainty of one fraction (variance σ) is large. However,
for a treatment course of few fractions, such as SBRT
treatment, dose delivery uncertainty must be reduced to
ensure that dose delivered to patient is close to the
expected value.
For example, suppose that the mean dose delivered to a
patient over a treatment course is required to be within
3% of the expected value with a 95% confidence level, then
2σN ¼ 2σﬃﬃﬃNp ¼ 3% and σ ¼ 1:5% ﬃﬃﬃﬃNp . If the number of
fractions is 30, the treatment quality can be maintained as
long as the delivery uncertainty (standard deviation) is
within 8.2%. However, if the number of fractions is 3 as in
many SBRT treatments, the delivery uncertainty must be
reduced to 2.6% to ensure treatment quality. Assuming
that the uncertainty σothers from all other sources is 2%,
the machine delivery uncertainty should be controlled
below
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
8:2%ð Þ2− 2%ð Þ2
q
¼ 7:6% to achieve the 3% criteria
for the 30 fractions of treatment; while for a SBRT treat-
ment of 3 fractions, the machine delivery uncertainty must
be controlled below
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2:6%ð Þ2− 2%ð Þ2
q
¼ 1:7% , a much
higher requirement than the conventional treatment of30 fractions. Apparently, if σothers is higher than 2.6%,
there is no way to achieve the expected treatment accur-
acy for the SBRT treatments and measures have to be
taken to reduce σothers.
Eqn. 9 can be further expanded to infer the probability
of difference between a given dose value and the mean
dose over a course of treatment from the pre-treatment
QA results as follows. Assuming RN ¼ RGiven 1þ δ%ð Þ,
where δ can be either positive or negative,















p e−N t−Rð Þ2σ2 dt
where δ is the percent difference between a given dose
value (e.g., planned dose value ) and the expected mean
dose value delivered over N fractions. δ is different
from Δ which is the percent difference between a given
dose value and the expected dose value in a single
delivery.
Averaging over all possible values of R and σ using
equations and terms in sections a) and b),
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and where z% ≥ 0 and is desired accur-
acy to the given value.
Eqn. 10 establishes the statistical relationship for the
pre-treatment QA measurement results (n, Rn and σ n ),
the treatment mean dose from to-be-delivered treatment
course of N fractions, and the difference between the
treatment mean dose and a given (planned) dose value
Rgiven. In the cases where R and σm are evaluated to be
around Rn and E σ nð Þ within a very small interval of
high confidence level, Rn and E σ nð Þ can be used to
directly substitute R and σm in Eqn. 10, respectively,
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Eqn. 10 becomes
< P δ%j j≤z%ð Þ>R;σ























Using the formalisms presented in sections a) through d),
probabilities can be quantitatively derived for relationships
among the expected measurement value, a given value, and
the expected treatment mean dose over a treatment course
using the information readily available from the QA
measurement procedure, assuming there is not additional
patient treatment uncertainties. However, in clinical treat-
ments, the value of σothers needs to be carefully estimated
based on various factors such as immobilization devices,
IGRT devices, etc.
Application of the above-derived analytical method to
dosimetric and clinical PSIMRT plan verification QA
measurements
As a demonstration, the above derived equations were
used to analyze a clinical PSIMRT plan verification QA
procedure and to predict the expected treatment mean
dose over a treatment course. The QA measurements
were carried out using four 0.05 cc Exradin Model A1SL
ionization chambers and Standard Imaging 8 channel
TomoElectrometer (Standard Imaging, Middleton, WI) on
a Tomothearpy Hi-Art™ machine (Tomotherapy-Accuray,
Madison, WI). The four chambers were positioned inside
a “Cheese Phantom” (Tomotherapy-Accuray, Madison,
WI) at four locations of various dose gradients. The
measurements were repeated multiple times. Each of
the measurements was independent (meaning that the
measurements did not affect each other), and the equip-
ment was identical for each measurement. Temperature
and pressure were corrected for all the measurements.
The variance in a QA measurement procedure is attrib-
uted to the variances of both machine delivery and meas-
urement instruments. However, during a treatment course
the variance of measurement instruments are absent while
patient setup uncertainty can also contribute to the treat-
ment variance. To simulate the patient setup variance to a
limited extent, some of the QA measurements presented
in the following section were conducted by re-setting
the phantom position and then taking measurements.
Certainly, this simulation could underestimate the degrees
of uncertainty in patient setup since unlike phantompatient body is generally not rigid and may also experience
intra-fractional motion.
Results
The results presented in this study were measured after
careful examinations of the machine and measurement
instruments to ensure they functioned normally and
within specification. If large deviations in the results
were observed, investigations were also conducted on
the machines and instruments to verify their working
integrity.
Statistical analysis of the accuracy of dose QA
measurement results
Table 1a and 1b present the results and statistical analysis
of the dose measurement procedure for two of the four
ionization chambers. The results from the other two
chambers were very similar to those of Chamber 1 and
are not presented. The doses from the plan were 1.702
and 0.546 Gy, respectively, at the corresponding points of
Chambers 1 and 2. The measurements were conducted
independently after initially setting up the phantom
and without resetting up the phantom between each
measurement.
The statistical results were presented for the measure-
ment accuracy analysis. The measurement accuracy was
defined as the percent difference between the expected
dose value (not the plan value) and the measurement
mean value. The analysis estimated the expected dose
delivered from the machine assuming that the measure-
ment instruments had minimal uncertainties.
In the tables, columns 1 to 7 are, respectively, the
measurement sequence number n (n =1, 2, … , 6),












estimated expected dose delivery standard deviation, the
probability Pn(PDR ≤ 2%), and the probability Pn(PDR ≤ 3%)
computed from Eqn. 5. Pn(PDR ≤ 2%) and Pn(PDR ≤ 3%)
were the probabilities of the measurement accuracy being
better than 2% and 3%, respectively, if their corresponding
mean values were used for the expected value after n
measurements.
Using the measurement results from Chamber 1 as an
example, the systematic analysis for this particular meas-
urement process can be described as follows. According
to Eqns. 1–4 and intuitively, it is improbable to evaluate
the accuracy using just the very first measurement reading
1.706 Gy. After the second reading was taken (1.695 Gy),
the mean value of the two readings was 1.700 Gy. Using
Eqn. 5, the probability of percent difference between this
mean value and the expected measurement value being
less than 2% was 89.63%. In other words, there was






value (1 to n)
Result standard





mean to be within
2% accuracy (1 to n)
Probability for the
mean to be within
3% accuracy (1 to n)
a. Chamber 1: corresponding plan dose was 1.702 Gy
1 1.706 1.706 - - -
2 1.695 1.700 0.008 0.010 89.63% 93.05%
3 1.695 1.699 0.006 0.007 98.85% 99.50%
4 1.689 1.696 0.007 0.008 99.76% 99.93%
5 1.689 1.695 0.007 0.007 99.96% 99.98%
b. Chamber 2: corresponding plan dose was 0.546 Gy
1 0.513 0.513 - - -
2 0.507 0.510 0.005 0.006 80.50% 86.76%
3 0.504 0.508 0.005 0.006 93.11% 96.77%
4 0.504 0.507 0.005 0.005 97.94% 99.33%
5 0.502 0.506 0.005 0.005 99.25% 99.83%
The measurements were conducted without the QA phantom re-setup between each measurement and the statistical analysis was for the accuracy of
measurement itself. The accuracy is defined as percent difference between the expected value and measurement mean value.
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was better than 2%. With a third measurement (1.695),
that probability (or confidence level) increased to 98.85%.
As more readings were taken, this probability increased.
Assuming that the accuracy requirement for this particular
measurement process was 2% and confidence level require-
ment was 95%, it is apparent that in this particular case 3
measurements had to be conducted to achieve the confi-
dence level to substitute the measured mean value for the
expected value. However, if the required confidence level
was still 95% but the required accuracy was 3%, 2 total
measurements, instead of 3, would have been adequate
(column 7 of Table 1).
Similar analysis can be performed for Chamber 2
measurements.
Table 2a and 2b present similar results for Chambers 1
and 2 in a little different measurement design. Instead of
leaving phantom untouched between each measurement,
the phantom, along with the chambers (which were
embedded inside the phantom) was reset up and realigned
between each measurement. This measurement design
was intended, to a limited degree, to simulate the setup
uncertainty. As expected, the standard deviations of the
corresponding results were larger. After 5 measurements,
the confidence levels to achieve an accuracy of 3% were
83.87% and 82.01%, respectively, for Chambers 1 and 2
measurements; and were 95.41% and 94.62%, respectively,
for an accuracy of 5%. If the setup uncertainty was taken
into account, 5 measurements were still inadequate to
derive a mean value with which the expected dose value
was within 3% of the mean value at 95% confidence level;
however, the 5 measurements were sufficient if the accur-
acy requirement was 5% at the confidence level of 95%.Statistical analysis of the differences between
measurement dose and corresponding plan dose
Following Equations 6, 7 an 8, Table 3 present the statis-
tical analysis results for the percent differences between the
plan doses and the expected doses delivered from the
machine at the locations of Chambers 1 and 2. The results
in Table 3a and 3b correspond to the measurements
without the phantom reset up, while those in Table 3c
and 3d were with the phantom being reset up and
realigned.
It should be re-emphasized that the plan dose is not at
all necessarily equal to the expected dose delivered from
the machine.
Without taking the phantom re-setup into account
(Table 3a), at the location of Chamber 1, two measure-
ments were adequate to have high confidence (95.81%)
that the expected machine delivery dose would be within
5% of the corresponding plan dose; after three measure-
ments, one would have high confidence (99.49%) that it
would be within 3% of the plan dose. However, with the
uncertainty caused by the phantom re-setup taken into
account, although the mean value of the five measure-
ments was well within 3% (−2.2%) of the plan dose, the
confidence level (65.01%) was fairly low for the expected
delivery dose being within 3% of the plan dose. The confi-
dence level was only 90.52% for the expected delivery dose
to be within 5% of the plan dose after 5 measurements.
These results demonstrate that simple comparison of
measured mean value to a given value is insufficient to
draw a statistically meaningful conclusion about the
difference between the expected measurement value
and the given value. Appropriate statistical analysis has to
be conducted.






value (1 to n)
Result standard





mean to be within
3% accuracy (1 to n)
Probability for the
mean to be within
5% accuracy (1 to n)
a. Chamber 1: corresponding plan dose was 1.702 Gy
1 1.689 1.689 - - -
2 1.706 1.698 0.012 0.015 89.62% 93.73%
3 1.550 1.648 0.086 0.097 57.74% 76.25%
4 1.700 1.661 0.075 0.081 72.60% 88.76%
5 1.678 1.665 0.065 0.069 83.87% 95.41%
b. Chamber 2: corresponding plan dose was 0.546 Gy
1 0.502 0.502 - - -
2 0.466 0.484 0.025 0.032 43.55% 59.61%
3 0.457 0.475 0.024 0.027 59.52% 77.70%
4 0.465 0.473 0.020 0.022 75.01% 90.16%
5 0.453 0.469 0.019 0.021 82.01% 94.62%
The measurements were conducted with the QA phantom re-setup and re-aligned between each measurement and the statistical analysis was for the accuracy of
measurement itself. The accuracy is defined as percent difference between the expected value and measurement mean value.
Table 3 Patient specific IMRT QA absolute dose measurement analysis
Meas. num (n) Percent difference between
the mean and plan dose (%, 1 to n)
Probability for the mean to be
within 3% of plan value (1 to n)
Probability for the mean to be
within 5% of plan value (1 to n)
a. Chamber 1: corresponding plan dose was 1.702 Gy. No QA phantom re-setup between each measurement.
1 0.232 - -
2 −0.095 93.05% 95.81%
3 −0.205 99.49% 99.84%
4 −0.341 99.93% 99.97%
5 −0.423 99.98% 99.98%
b. Chamber 2: corresponding plan dose was 0.546 Gy. No QA phantom re-setup between each measurement.
1 −5.960 - -
2 −6.551 3.28% 9.96%
3 −6.939 0.70% 3.12%
4 −7.132 0.10% 0.70%
5 −7.319 0.02% 0.17%
c. Chamber 1: corresponding plan dose was 1.702 Gy. The QA phantom was re-setup between each measurement.
1 −0.751 - -
2 −0.259 89.57% 93.72%
3 −3.153 39.74% 65.16%
4 −2.388 55.53% 81.86%
5 −2.193 65.01% 90.52%
d. Chamber 2: corresponding plan dose was 0.546 Gy. The QA phantom was re-setup between each measurement.
1 −8.065 - -
2 −11.327 4.76% 8.88%
3 −12.963 1.69% 3.35%
4 −13.432 0.39% 0.85%
5 −14.164 0.07% 0.18%
Statistical analysis results for the percent difference between the expected delivery value and given (plan) value.
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http://www.ro-journal.com/content/8/1/225As shown in Table 3b and 3d, it was statistically im-
possible for the expected delivery dose at the location of
Chamber 2 to be within 5% of the corresponding plan
dose. A different physical quantity such as Gamma Index
[22] needs to be used for the QA outcome evaluation.Statistical estimation of the difference between plan dose
and the average dose delivered over a treatment course
Table 4 show the results of statistical estimation of the
differences between plan dose and the average dose
delivered over a treatment course at the locations of
Chambers 1 and 2. These results could be used to estimate
the difference between plan dose and the corresponding
dose delivered to patient over a treatment course. The
results were derived from Eqn. 11 using the QA measure-
ment data. Two types of treatment course were analyzed:
one with 36 fractions, similar to a conventional treatment
course; the other with 3 fractions, similar to the frac-
tionation scheme in a SBRT treatment course. Simi-
larly, Table 4a,b,c and d are correspondent to the




Probability for the mean
to be within 1% of plan value
P
to b
a. Estimation at the point corresponding to Cham
No QA phantom re-setup between each measuremen
36 20.23%
3 40.59%
b. Estimation at the point corresponding to Cham
No QA phantom re-setup between each measureme
36 0.00%
3 0.00%
c. Estimation at the point corresponding to Cham
The QA phantom was re-setup between each measurem
36 8.21%
3 23.89%
d. Estimation at the point corresponding to Cham
The QA phantom was re-setup between each measurem
36 0.00%
3 0.00%
e. Estimation at the point corresponding to Cham
The QA phantom was re-setup between
uncertainty was included. The mean m
36 18.55%
3 18.69%
f. Estimation at the point corresponding to Cham
The QA phantom was re-setup between each measure
The mean measured valu
36 0.00%
3 0.01%respectively. In Table 4e and f, on top of the QA meas-
urement uncertainties introduced from dose delivery and
phantom re-setup, an additional 5% random uncertainty
was added. This 5% of uncertainty was estimated to be
caused by other factors during patient treatment, such as
organ motion, body contour change, clinical patient setup,
etc. The overall standard deviations in Table 4e and f
were computed as σAll ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
σ2measurement þ 5% Rð Þ2
q
(13)
and used in Eqn. 12.
As expected, at the location of Chamber 2, regardless
of whether a conventional or SBRT treatment course was
to be delivered, it was nearly impossible for the average
treatment dose to be within 5% of the corresponding plan
dose (Table 4b, d and f).
At the location corresponding to Chamber 1, for the
conventional treatment course, even at the largest de-
viation (Table 4e), the average treatment dose was still
almost certain to be within 5% of the plan dose (confidence
level of 99.8%). With the deviation from the machine
delivery alone, it was almost guaranteed that the treat-
ment would be within 3% of the plan dose (Table 4a, theed dose and the average dose delivered over a
robability for the mean
e within 3% of plan value
Probability for the mean
to be within 5% of plan value
ber 1: corresponding plan dose was 1.702 Gy.
t. The mean measured value used was 1.684 Gy.
100.00% 100.00%
100.00% 100.00%
ber 2: corresponding plan dose was 0.546 Gy.
nt. The mean measured value used was 0.503 Gy.
0.00% 0.00%
0.00% 0.00%
ber 1: corresponding plan dose was 1.702 Gy.
ent. The mean measured value used was 1.669 Gy.
94.12% 100.00%
65.58% 90.16%
ber 2: corresponding plan dose was 0.546 Gy.
ent. The mean measured value used was 0.471 Gy.
0.00% 0.00%
0.00% 0.00%
ber 1: corresponding plan dose was 1.702 Gy.
eachmeasurement and additional 5%
easured value used was 1.669 Gy.
84.00% 99.80%
52.33% 76.72%
ber 2: corresponding plan dose was 0.546 Gy.
ment and additional 5% uncertainty was included.
e used was 0.471 Gy.
0.00% 0.00%
0.06% 0.40%
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was added (Table 4c), that confidence level dropped to
94%. If the additional 5% clinical uncertainty was further
taken into account (Table 4c), the confidence level to be
within 3% decreased to 84%, indicating there was a need
to reduce clinical uncertainty to ensure treatment quality.
For the assumed SBRT treatment course, the uncertainty
caused by the phantom re-setup alone brought the confi-
dence levels of the 3% and 5% from 100% down to 65.58%
and 90.16%, respectively (Table 4a and c). The additional
5% clinical uncertainty decreased the confidence levels
even further to 52.33% and 76.72%, respectively. These
results indicated that to ensure SBRT treatment quality as
planned there is a need to apply more stringent require-
ment to minimize any source of uncertainties.
From Table 4a, c and e, it is interesting to note that
with the same amount of treatment uncertainty the confi-
dence levels were higher for the SBRT treatment course to
achieve high level of treatment accuracy (e.g., within 1% of
the plan dose) than the conventional treatment course. It
can be explained by the fact that the standard deviation
of the average delivery dose in a SBRT treatment course
is larger than that of a conventional treatment course
(according to Eqn. 11) and the larger standard deviation
leads to a broader distribution which may be more likely
to span over the plan dose.
Discussion
This study is to establish a model taking the radiation
delivery random errors into account. Even after taking the
random errors into account, the expected measurement
result may still differ from the corresponding planning
quantity. This difference is likely caused by the systematic
errors that originate from different sources, such as plan-
ning algorithm inaccuracy, machine calibration deviation,
etc. These systematic errors can be potentially significant.
One of the major purposes of dosimetry measure-
ments is to identify the expected value of the subject of
measurement. For certain measurement procedures
such as PSIMRT plan verification QA, this expected
value of measurement may then be compared to a
given value from the treatment plan. The expected value
can only be quantified using measurement results, such as
the mean and standard deviation, by using statistical
concepts like probability, confidence level, and interval.
Although a single measurement may provide a numerical
value for the subject of measurement, its statistical rele-
vance and significance is impossible to define. To obtain
statistically meaningful results, at least two independent
measurements must be performed.
From a statistical perspective, the number of measure-
ments should not be predetermined. What should be
predetermined are the desired confidence level and inter-
val based on required dosimetric accuracy. The number ofrequired measurements is then dependent on the meas-
urement variance and the chosen confidence interval
and level. According to the results presented in Results
Section 3.1, it is obvious that smaller measurement de-
viations require a fewer number of required measurements.
Percent accuracy tolerances have been recommended
for radiation treatment beam calibrations and PSIMRT
plan verification QA [6,8,9]. During those procedures, the
current practice is to take measurement(s) and compare
the mean values to corresponding desired values (e.g.,
IMRT planned dose values or 1 cGy/MU in the case of
machine calibration measurements). Decisions are then
made based on whether the values are within tolerance.
As demonstrated in the previous sections, this type of
decision-making may be flawed since the confidence level
of such accuracy is very dependent on the measured vari-
ance and number of measurements, and so should be
evaluated based on not only simple comparison of the
mean values to the given values but also measurement
details such as measurement deviations and number of
measurements. Moreover, it is anticipated that the doses
delivered according to an IMRT treatment plan vary from
fraction to fraction and exhibit a statistical distribution
even if all machine components function within specifica-
tions. The standard deviation of this distribution may be
influenced by several factors, such as machine delivery
variation, patient setup variation, patient organ motion
and body contour change, etc. On the other hand, IMRT
treatment consists of a limited number of fractions, some-
times only a few fractions (e.g., Stereotactic Body Radio-
therapy). The standard deviation of the expected average
dose over a treatment course is not only dependent on the
standard deviation of individual treatments but also highly
dependent on the number of fractions (Eqn. 9). Thus,
evaluation of a QA measurement outcome should also
take into consideration the details of the treatment course
for which the QA is performed. For example, as shown in
Table 3c, after five QA measurements, the percent differ-
ence between the average QA result and the correspond-
ing plan dose was less than 3% (−2.19%). Using the
common practice of direct comparison with a preset toler-
ance of 3%, one would likely draw a conclusion that the
QA result was acceptable. However, based on the statis-
tical analysis, it was found that the confidence level was
only 65% for the expected dose to be within 3% of the plan
dose in an individual dose delivery, making it a little diffi-
cult to decide whether the plan was indeed acceptable for
patient treatment. On the other hand, if the treatment
course consisted of 36 fractions, the confidence level was
94% for the expected average treatment dose to be within
3% of the plan dose (Table 4c). In this case, the QAed plan
could be deemed acceptable for this treatment course.
Conversely, if the treatment course consisted of only 3
fractions, the confidence level was only 65.6% for the
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over this hypo-fractionated course. In this later case,
whether or not the QAed plan should be used for treat-
ment might become questionable and action might be
required to either modify the plan or adjust the beam
delivery system to ensure treatment quality.
In a typical PSIMRT plan verification QA procedure,
there is more than one point of interest that is evaluated
by measurement and compared to a corresponding plan
value. Thus, the decision making process is actually more
difficult than the cases presented in this study. On the
other hand, the basic principle still holds that a single
measurement showing agreement or disagreement with
the corresponding plan value cannot be used to draw a
definitive conclusion in the pass or failure of the PSIMRT
plan verification QA.
The purpose of PSIMRT plan verification QA is to verify
the accuracy and precision of plan delivery. The current
standard for PSIMRT plan verification QA verifies only
the accuracy of plan delivery without providing statistical
details. The ultimate goal of the plan QA is to ensure
that the average dose delivered over a treatment course
is within a desired tolerance with the plan. According to
the proposed method, determining the accuracy of an
IMRT plan requires multiple measurements and the in-
formation about the treatment course itself. The standard
deviation in Eqns 10 and 11 should contain the contribu-
tions from various uncertainty sources, such as machine
delivery, patient setup, anatomic motion and deformation,
day-to-day machine variations, etc. Unfortunately, the
only component that the conventional QA measurements
can detect relatively accurately is the machine plan delivery
variation. Therefore, a more reasonable way of evaluating a
QA outcome may be as follows. First, a desired accuracy
tolerance (e.g., the percent dose difference between plan
and average delivery dose) with a specified confidence level
is decided upon for the to-be-QAed treatment course. Sec-
ond, a percent standard deviation (uncertainty) is estimated
for the clinical patient treatment based on the patient
anatomy study and motion evaluation (e.g., 4DCT for
motion analysis), day-to-day machine stability, estimated
patient setup variation, etc. Third, two QA measurements
are performed and the results are analyzed using
Eqns. 9–13. Fourth, if the subsequent confidence level
does not meet the specified confidence level for the desired
accuracy, additional QA measurements are conducted and
the results are analyzed until no improvements in the confi-
dence level are seen. Fifth, if the confidence level still does
not meet the specified level, either the clinical patient treat-
ment uncertainty needs to be further reduced or the plan
needs to be revised.
In the analysis throughout the current study, measure-
ment equipment uncertainty was not taken into account.
If equipment random uncertainty (denoted as σequip) isknown, the measurement deviation for the subject of







If equipment is found to contribute to systematic errors,
they should be identified and corrected for.
Dose distributions in conformal radiation treatments
(e.g., IMRTand 3DCRT) can exhibit signification variations.
Although the presented method is applicable to any point
inside a phantom/patient, the derived statistical results
most likely vary at different locations. Thus, a more com-
prehensive three dimensional approach is required to
analyze the dose coverage inside a patient. This three
dimensional analytical approach, taking many points into
consideration, is beyond the scope of the current study
and is subject to further investigation.
QA device is available now to simultaneously measure
delivered doses at many different points. In principle, it is
reasonable to utilize the measurement results at numerous
points to derive the delivery variance, assuming that the
dose measurement equipment is perfect. Unfortunately,
the currently available measurement equipment has its
own intrinsic limitations. Depending on the measurement
region (e.g. high dose gradient regions vs low dose gradi-
ent regions), the variance introduced by the measurement
equipment can be different at different locations. Careful
analysis is required to utilize the measurement results at
number locations for this purpose. On the other hand,
the measurement results, obtained from many comparable
patient QA measurements, can be useful to estimate the
variance. The method and analysis presented in this study
require two conditions: 1) measurements are independent
and 2) the measurement results are normally distributed.
The first condition is easily satisfied since one measure-
ment does not affect the others, while the second condi-
tion is still an assumption, though generally accepted. If
measurement of a subject of interest is proven to having
something other than a normal distribution, the results
and conclusions from the current study are not applicable.
The analysis presented above assumed that the differ-
ence in dose calculated for a QA phantom relative to the
dose actually delivered by that machine to the phantom, is
similar to the difference in dose calculated for a patient
relative to the dose delivered to the same rigidly posi-
tioned patient by the same machine. This assumption is
approximately true given that the phantom materials
are similar to patient tissues. However, it needs to be
again emphasized that there exist other errors, such as
uncertainties in CT numbers, anatomical changes be-
tween simulation and treatment and during treatment,
beam calibration variation, etc [18], which may lead to
additional overall dose delivery uncertainty.
We acknowledge that although we believe our method to
be scientifically sound it clearly will add to the workload of
medical physicists and its practicality remains to be
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dosimetric verification is not carried out for every patient
but only in a limited number of complicated cases. There-
fore the feasibility of implementing the methods described
in this work to assess PSIMRT QA results, although valid
from a theoretical/methodological point of view, would
have to be evaluated in the clinical scenario and perhaps
combined with a population systematic and random er-
rors based approach (van Herk, 2004) [23]. On the other
hand, if the QA passing tolerance is established and deliv-
ery process uncertainty is established in a department,
with the developed method, one QA measurement result
should yield to a probability value for the QA to pass. If
the probability value is higher than a certain acceptable
level (e.g., 95%), no additional measurement is needed.
The results of the current study were based on the
assumptions that there were no human errors and that
the user’s equipment was in good condition during mea-
surements. If the measurement deviation is larger than
usual, equipment malfunction must be ruled out. Rote
adherence to this statistical method and approach without
careful examination and analysis could lead to serious
errors. It is also noticed that the some measurement data
presented in this study exhibited certain non-randomness.
It could be coincidence since all involved equipment were
carefully evaluated and underwent adequate warm-up
process before measurements.Conclusions
By acknowledging and considering the statistical nature of
multi-fractional delivery of radiation treatment, we have
established and demonstrated a quantitative methodology
to evaluate the PSIMRT QA results. Both the statistical
parameters associated with QA measurement procedures
and the treatment course itself need to be taken into
account to evaluate the QA outcome and to determine
whether the plan is acceptable and whether additional
measures should be taken to reduce treatment uncertain-
ties. The result from a single QA measurement without
statistical analysis can be misleading. When the required
number of measurements is comparable to the planned
number of fractions and the variance is unacceptably high,
action must be taken to either modify the plan or adjust
the beam delivery system.Competing interests
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